ES2191070T3 - Arilalquil-piridazinonas. - Google Patents

Arilalquil-piridazinonas.

Info

Publication number
ES2191070T3
ES2191070T3 ES96105702T ES96105702T ES2191070T3 ES 2191070 T3 ES2191070 T3 ES 2191070T3 ES 96105702 T ES96105702 T ES 96105702T ES 96105702 T ES96105702 T ES 96105702T ES 2191070 T3 ES2191070 T3 ES 2191070T3
Authority
ES
Spain
Prior art keywords
sup
piridazinonas
arilalquil
phosphodiestarasa
allergies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96105702T
Other languages
English (en)
Inventor
Rochus Dr Jonas
Michael Dr Wolf
Norbert Dr Beier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191070T3 publication Critical patent/ES2191070T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ARILALQUIL-PIRIDAZINONAS DE FORMULA I Y SUS SALES FISIOLOGICAMENTE ACEPTABLES EN DONDE R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUP,4}, R{SUP,5} Y Q TIENEN LOS SIGNIFICADOS DADOS EN LA REIVINDICACION 1, POSEEN UN EFECTO INHIBIDOR DE LA FOSFODIESTARASA IV Y SE PUEDEN UTILIZAR EN EL TRATAMIENTO DE PROCEDIMIENTO INFLAMATORIOS ASI COMO EN ALERGIAS, ASMA Y ENFERMEDADES AUTOINMUNES.
ES96105702T 1995-04-20 1996-04-11 Arilalquil-piridazinonas. Expired - Lifetime ES2191070T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19514568A DE19514568A1 (de) 1995-04-20 1995-04-20 Arylalkyl-pyridazinone

Publications (1)

Publication Number Publication Date
ES2191070T3 true ES2191070T3 (es) 2003-09-01

Family

ID=7759974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96105702T Expired - Lifetime ES2191070T3 (es) 1995-04-20 1996-04-11 Arilalquil-piridazinonas.

Country Status (21)

Country Link
US (2) US6399611B1 (es)
EP (1) EP0738715B1 (es)
JP (1) JP4005157B2 (es)
KR (1) KR100428879B1 (es)
CN (1) CN1159299C (es)
AT (1) ATE231842T1 (es)
AU (1) AU705025B2 (es)
CA (1) CA2174472C (es)
CZ (1) CZ291868B6 (es)
DE (2) DE19514568A1 (es)
DK (1) DK0738715T3 (es)
ES (1) ES2191070T3 (es)
HU (1) HU226198B1 (es)
NO (1) NO307931B1 (es)
PT (1) PT738715E (es)
RU (1) RU2159236C2 (es)
SI (1) SI0738715T1 (es)
SK (1) SK284167B6 (es)
TW (1) TW475927B (es)
UA (1) UA43853C2 (es)
ZA (1) ZA963154B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533975A1 (de) * 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
JP4017214B2 (ja) 1996-06-11 2007-12-05 興和創薬株式会社 ５−フェニル−３−ピリダジノン誘導体
EP0924204A4 (en) * 1996-08-27 2002-10-23 Nikken Chemicals Co Ltd 2-PHENYLMORPHOLIN-5-ON DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
AU754253B2 (en) * 1998-10-06 2002-11-07 Dainippon Pharmaceutical Co. Ltd. 2,3-disubstituted pyridine derivatives, processes for the preparation thereof, pharmaceutical compositions containing the same and intermediates therefor
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
EP1212089B1 (en) 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistic combination of roflumilast and salmeterol
RU2279428C2 (ru) * 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов
DE10064997A1 (de) * 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20050070529A1 (en) * 2001-02-12 2005-03-31 Merk Pantent Gmbh Use of type 4 phosphodiesterase inhibitors in myocardial diseases
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7074959B2 (en) * 2002-08-01 2006-07-11 New Mexico Highlands University Methods and systems for remediating hydrazine-contaminated equipment and/or surfaces
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
EP1716133B1 (en) 2004-02-04 2008-03-26 Nycomed GmbH 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
WO2005075437A1 (en) * 2004-02-04 2005-08-18 Altana Pharma Ag Pyridazinone derivatives and their use as pde4 inhibitors
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2383239T3 (es) * 2006-12-14 2012-06-19 Astellas Pharma Inc. Compuestos de ácidos policíclicos útiles como antagonistas de CRTH2 y como agentes antialérgicos
US8466198B2 (en) * 2008-09-02 2013-06-18 Bruce Kneller Compositions comprising creatine salts and methods of use thereof
EP3001912A1 (en) * 2009-08-26 2016-04-06 Jeffrey M. Golini Pharmaceutical or nutraceutical composition
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
BR112021000395A2 (pt) 2018-07-11 2021-04-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compostos imunomoduladores diméricos contra mecanismos baseados em cereblon

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604863A (es) * 1967-11-22 1972-04-17
US3975388A (en) * 1971-02-22 1976-08-17 Bdh Pharmaceuticals Limited Pyridazinones
GB1488330A (en) * 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
DE2845456A1 (de) * 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
US4397854A (en) * 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
SU1313346A3 (ru) * 1981-09-17 1987-05-23 Варнер-Ламберт,Компани (Фирма) Способ получени замещенных 6-арил-3(2 @ )-пиридазинонов
US4734415A (en) * 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
NZ208107A (en) * 1983-05-11 1986-12-05 Byk Gulden Lomberg Chem Fab 6-aryl-3(2h)-pyridazinones and pharmaceutical compositions
US4666902A (en) * 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
JPS61158969A (ja) * 1984-12-24 1986-07-18 ワーナー‐ランバート・コンパニー ４，５‐ジヒドロ‐４，４‐ジアルキル‐６‐（置換）フエニル‐３（２ｈ）‐ピリダジノン類
DE3704879A1 (de) * 1987-02-17 1988-08-25 Merck Patent Gmbh Pyridazinonderivate
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
PT94954A (pt) * 1989-08-10 1991-04-18 Glaxo Inc., Processo para a preparacao de derivados de piridazinona
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JP2806192B2 (ja) * 1992-11-02 1998-09-30 日本曹達株式会社 血小板凝集抑制剤
DE19502699A1 (de) 1995-01-28 1996-08-01 Merck Patent Gmbh Arylalkyl-thiadiazinone

Also Published As

Publication number Publication date
NO961578L (no) 1996-10-21
US6531473B2 (en) 2003-03-11
SK284167B6 (sk) 2004-10-05
NO961578D0 (no) 1996-04-19
HUP9601034A2 (en) 1996-12-30
JPH08291145A (ja) 1996-11-05
SI0738715T1 (en) 2003-10-31
CA2174472A1 (en) 1996-10-21
EP0738715A3 (de) 1998-06-17
CN1142493A (zh) 1997-02-12
DE19514568A1 (de) 1996-10-24
AU5071196A (en) 1996-10-31
CZ291868B6 (cs) 2003-06-18
HU9601034D0 (en) 1996-06-28
HUP9601034A3 (en) 1999-03-01
EP0738715B1 (de) 2003-01-29
KR960037662A (ko) 1996-11-19
PT738715E (pt) 2003-06-30
TW475927B (en) 2002-02-11
CA2174472C (en) 2008-10-21
ATE231842T1 (de) 2003-02-15
US6399611B1 (en) 2002-06-04
SK48796A3 (en) 1997-02-05
JP4005157B2 (ja) 2007-11-07
CN1159299C (zh) 2004-07-28
HU226198B1 (en) 2008-06-30
NO307931B1 (no) 2000-06-19
CZ113296A3 (en) 1996-11-13
US20020111356A1 (en) 2002-08-15
DE59610081D1 (de) 2003-03-06
UA43853C2 (uk) 2002-01-15
DK0738715T3 (da) 2003-05-26
KR100428879B1 (ko) 2004-07-15
AU705025B2 (en) 1999-05-13
RU2159236C2 (ru) 2000-11-20
EP0738715A2 (de) 1996-10-23
ZA963154B (en) 1996-12-06

Similar Documents

Publication Publication Date Title
ES2191070T3 (es) Arilalquil-piridazinonas.
ES2192213T3 (es) Arilalquil-diazinonas como inhibidores de fosfodiesterasa iv.
ES2191192T3 (es) Tienopirimidinas.
ES2189235T3 (es) 6-fenilfenantridinas sustituidas.
ES2162942T3 (es) Nuevos derivados de acidos carboxilicos, su obtencion y empleo.
ES2152414T3 (es) Dihidrobenzofuranos.
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
SE9504661D0 (sv) New compounds
YU21401A (sh) Tetrahidropiridoetri
ES2184077T3 (es) Nuevas fenantridinas sustituidas en la posicion 6.
EP1689406A4 (en) HETEROCYCLIC INHIBITORS OF MEK AND METHOD FOR THEIR APPLICATION
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
MA28010A1 (fr) Derives de piperazine et leur utilisation comme agents therapeutiques
DE60045508D1 (de) Dalda-analoge und ihre verwendung
SE9802208D0 (sv) Novel compounds
EP1799227A4 (en) THERAPEUTIC AGENTS FOR TARGETING THE NC CA ATP CHANNEL AND USE METHOD THEREFOR
ES2163735T3 (es) Compuestos biarilos heterociclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
IS2077B (is) Tetrahýdrópýridóefnasambönd
EP1551392A4 (en) NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
ES2164765T3 (es) Heterociclilbenzonitrilos.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
SE9802209D0 (sv) Novel compounds